A composition containing quinoline TGF-β1 inhibitor and its use
A pharmaceutical composition of a quinoline TGF-β1 inhibitor with a disintegrant, lubricant, and filler addresses solubility and bioavailability issues, enhancing therapeutic efficacy for TGF-βR1-related diseases while minimizing side effects.
Patent Information
- Application Number
- CN202110414852.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-04-17
- Filing Date
- 2021-04-17
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-04-17
AI Technical Summary
Current TGF-βR1 inhibitors exhibit low target selectivity and specificity, leading to off-target toxic side effects, and existing preparations of quinoline TGF-β1 inhibitors face issues with stability, solubility, and bioavailability.
A pharmaceutical composition comprising a quinoline TGF-β1 inhibitor (4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoline or its solvate or crystal, combined with a disintegrant, lubricant, and filler, to enhance solubility and bioavailability, and minimize impurities.
The composition achieves complete dissolution, high bioavailability, and stability under various conditions, suitable for treating TGF-βR1-related diseases such as cancer and fibrosis, with reduced off-target toxicity.
Smart Images

Figure CN113521074B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical preparations, and relates to a composition comprising a quinoline TGF-β1 inhibitor and a use thereof, and specifically relates to a pharmaceutical composition comprising 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)quinoline or a solvate or crystal thereof. Background Art
[0002] TGF-β (transforming growth factor β) is an important cytokine. So far, six different subtypes (TGF-β1 to 6) have been discovered, with different homology between them. In mammals, only three subtypes are expressed, namely TGF-β1, TGF-β2 and TGF-β3. It is a multifunctional growth factor superfamily with a wide range of biological activities, participating in early embryonic development, cartilage and bone formation, extracellular matrix synthesis, inflammation, interstitial fibrosis, regulation of immune and endocrine functions, and tumor formation and development. At the same time, these three isomers are similar in structure, and their amino acid sequences are highly homologous, but in their respective gene knockout mouse models, they show completely different phenotypes, suggesting that each isomer has specific and non-intersecting functions in vivo. The ligands of the TGF-β family can bind to receptors on the membrane surface to initiate the transmission of downstream signals in cells.
[0003] TGF-β1 is the most common and important subtype of TGFβ. It is the most abundant subtype in the liver and the strongest known inducing factor of liver fibrosis. It plays a pivotal role in the development of chronic liver disease to end-stage liver disease (Yamazaki, et al. Digestive Disease, 2011, 29: 284-288). Many studies have shown that TGF-β1 and TGFβ receptors are usually highly expressed in liver disease organs, blood vessels and extracellular matrix. In the classic TGFβ-TGFβR-Smads pathway, TGF-β1 activates TGFβR1 (transforming growth factor β receptor 1, ALK5) in the signaling pathway, thereby regulating the entire signaling pathway and regulating the expression of a series of target genes related to fibrosis and tumor development. It is generally believed that TGF-β promotes liver cancer mainly by promoting tumor cell metastasis, enhancing tumor cell immune escape and inducing angiogenesis (Ling, et al. Current Pharmaceutical Biotechnology, 2011, 12: 2190-2202).
[0004] Drug research targeting the TGF-β pathway has been conducted for many years, but TGFβR1 inhibitors such as Galunisertib have shown certain cardiotoxicity (such as bleeding, functional degradation, inflammatory damage, etc.) in animal models. The reason is that the target selectivity and specificity of this type of drug are low. While inhibiting the TGFβR1 kinase activation site, the drug also has a strong inhibitory effect on other proteins with the same kinase region (such as p38α), which in turn produces many unexpected off-target toxic side effects. Therefore, there is still a need to develop more selective TGFβR1 inhibitors to specifically regulate the TGF-β signaling pathway for the treatment of TGF-β-related diseases. Summary of the invention
[0005] The inventors of the present invention have discovered a quinoline TGF-β1 inhibitor, the compound structure of which is shown in the following formula (I), and the chemical name is 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoline (hereinafter referred to as "the compound of formula (I)"):
[0006]
[0007] The inventors of the present invention have found that the compound of formula (I) or its hydrate, solvate or crystal exhibits significant inhibitory activity against TGF-βR1 kinase and is very promising as a therapeutic agent for TGF-βR1-related diseases.
[0008] So far, no suitable preparations containing the compound of formula (I) or its isomers or their pharmaceutically acceptable salts have been reported. As is well known in the art, many problems are faced in the preparation of such preparations, such as the long-term stability of the preparations, the control of related substances, the absorption and bioavailability of the drug, etc. These problems are determined by various factors, such as many factors that affect the absorption of the drug, including the dissolution or release of the drug from the preparation, the dissolution of the drug under physiological conditions, and the permeability of the gastrointestinal tract, etc.
[0009] Therefore, it is necessary to study the compound of formula (I) or its derivatives to provide suitable preparations that meet the clinical drug needs.
[0010] The inventors of the present invention found in previous studies that the compound of formula (I) has a strong electrostatic force, is easy to agglomerate in the dissolution medium, and dissolves slowly; in addition, the compound of formula (I) has poor solubility.
[0011] One object of the present invention is to provide a pharmaceutical composition comprising (a) a compound of formula (I) or a solvate or crystal thereof; and (b) a disintegrant. The pharmaceutical composition of the present invention can be completely dissolved when prepared as a formulation and has high bioavailability.
[0012] Another object of the present invention is to provide a pharmaceutical preparation containing the pharmaceutical composition of the present invention.
[0013] Another object of the present invention is to provide the use of the pharmaceutical composition of the present invention in the preparation of drugs for treating and / or preventing cancer, tissue proliferative diseases, fibrosis or inflammatory diseases.
[0014] To achieve the above purpose, the present invention provides the following technical solutions:
[0015] In one aspect, the present invention provides a pharmaceutical composition comprising:
[0016] (a) a compound of formula (I) or a solvate or crystal thereof,
[0017]
[0018] and (b) a disintegrant.
[0019] In some specific embodiments, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 1% to 80% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 3% to 40% (weight / weight), and further preferably about 5% to 10% (weight / weight).
[0020] In some specific embodiments, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 1% to 80% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 3% to 40% (weight / weight), and further preferably about 5% to 10% (weight / weight).
[0021] In some specific embodiments, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a solvate or crystal thereof and a disintegrant, wherein the disintegrant is selected from one or more of sodium starch glycolate (abbreviated as: CMS-Na), cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose (abbreviated as: CCNa) and low-substituted hydroxypropyl cellulose (abbreviated as: L-HPC), preferably selected from one or more of sodium starch glycolate, cross-linked sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose, and further preferably selected from sodium starch glycolate. It is well known in the art that within a certain range, as the amount of disintegrant increases, the disintegration of the capsule and the dissolution of the drug can be promoted, but after exceeding a certain amount, its disintegration-promoting effect will gradually weaken and even hinder the dissolution of the drug. Therefore, it is necessary to study the content and use method of the disintegrant so that the disintegrant can achieve the best disintegration effect. In some embodiments, the disintegrant in the pharmaceutical composition provided by the present invention accounts for about 1% to 30% (weight / weight) of the total weight of the pharmaceutical composition, preferably 2% to 15% (weight / weight), and more preferably 6% to 10% (weight / weight). The inventors of the present invention have found that the preparation prepared using the pharmaceutical composition of the present invention containing the above disintegrant can significantly improve the solubility of the compound of formula (I), and the preparation is stable in properties and has few impurities under high humidity, high temperature, light, accelerated and long-term test conditions.
[0022] In some embodiments, the pharmaceutical composition provided by the present invention further comprises a binder, and the binder is one or more of alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carboxymethylcellulose, powdered cellulose, gelatin, magnesium aluminum sulfate, maltodextrin, povidone, copovidone, hypromellose, hydroxypropyl cellulose, hydroxyethyl cellulose, methylcellulose, gum arabic, sodium alginate, guar gum, starch, pregelatinized starch or sucrose. More preferably, the binder is selected from one or more of povidone, hypromellose and hydroxypropyl cellulose. It is well known in the art that an appropriate amount of binder in the prescription can improve the hardness and fluidity of the granules after granulation, but too much dosage will make the granulation process difficult to control on the one hand, and the granules are easily over-wet, and on the other hand, it will also cause difficulty in disintegration of the granules, and the drug dissolution is slow, therefore, it is necessary to study the content of the binder. In some embodiments of the present invention, the binder in the pharmaceutical composition provided by the present invention accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 0.5% to 5% (weight / weight), more preferably about 0.5% to 1.5% (weight / weight), and even more preferably about 1% (weight / weight).
[0023] In some embodiments, the pharmaceutical composition provided by the present invention further comprises a lubricant, that is, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder and a lubricant, wherein the disintegrant has the definition described above, and the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talcum powder, polyethylene glycol, glyceryl behenate, glyceryl monostearate, stearyl palmitate, sodium lauryl sulfate and hydrogenated vegetable oil. More preferably, the lubricant is selected from one or more of magnesium stearate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol, talcum powder, sodium stearyl fumarate and glyceryl behenate. In some embodiments of the present invention, the lubricant in the pharmaceutical composition provided by the present invention accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 0.1% to 5% (weight / weight), more preferably about 0.3% to 2% (weight / weight), and even more preferably about 0.5% to 1.5% (weight / weight).
[0024] In some embodiments, the pharmaceutical composition provided by the present invention further comprises a filler, that is, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder, a lubricant and a filler, wherein the disintegrant and the lubricant have the definitions described above, and the filler is selected from one or more of microcrystalline cellulose (abbreviated as: MCC), powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol (abbreviated as: MAN), starch, lactose (abbreviated as: LAC), sugars, celluloses and inorganic salts. In some embodiments, the pharmaceutical composition of the present invention comprises two or more fillers, one of which is selected from microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate and pregelatinized starch, and the other fillers are selected from one or more of mannitol, starch, lactose, sugars, celluloses and inorganic salts. More preferably, the other fillers are selected from one or more of starch, dextrates, glucose, lactose, dextrin, fructose, maltose, sorbitol and mannitol. In some embodiments of the present invention, the filler in the pharmaceutical composition provided by the present invention accounts for about 0% to 95% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 40% to 90% (weight / weight), and more preferably about 60% to 88% (weight / weight). In some embodiments, the pharmaceutical composition of the present invention further comprises mannitol and microcrystalline cellulose, wherein the weight ratio of mannitol to microcrystalline cellulose is about 1:0.25 to about 1:8, preferably about 1:0.5 to about 1:4, and more preferably about 1:0.9 to about 1:2.
[0025] In some embodiments, the pharmaceutical composition provided by the present invention further comprises a wetting agent, that is, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant, a filler and a wetting agent, wherein the disintegrant, lubricant and filler have the definitions described above, and the wetting agent is water.
[0026] In some embodiments, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant and a filler.
[0027] In some embodiments, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant and a binder.
[0028] In some embodiments, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant and a lubricant.
[0029] In some embodiments, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant and a filler.
[0030] In some embodiments, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder, a lubricant and a filler.
[0031] In some embodiments, the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder, a lubricant, a filler and a wetting agent.
[0032] In some preferred embodiments, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 1% to 80% (weight / weight) of the total weight of the pharmaceutical composition, the disintegrant accounts for about 1% to 30% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 0% to 95% (weight / weight) of the total weight of the pharmaceutical composition. Further preferably, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 3% to 40% (weight / weight) of the total weight of the pharmaceutical composition, the disintegrant accounts for about 2% to 15% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0.5% to 5% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0.1% to 5% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 40% to 90% (weight / weight) of the total weight of the pharmaceutical composition. Still further preferably, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 5% to 10% (weight / weight) of the total weight of the preparation, the disintegrant accounts for about 6% to 10% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0.5% to 1.5% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0.3% to 2% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 60% to 88% (weight / weight) of the total weight of the pharmaceutical composition.
[0033] The present invention also provides a pharmaceutical preparation comprising the pharmaceutical composition of the present invention.
[0034] In some preferred embodiments, the pharmaceutical preparation of the present invention is a tablet, granule, powder, sustained release agent, pill, capsule, lozenge or cachet. In a specific embodiment, the sustained release agent is a sustained release pellet. In a specific embodiment, the pharmaceutical preparation of the present invention is a tablet, capsule or granule.
[0035] In some preferred embodiments, the present invention provides a pharmaceutical preparation comprising a pharmaceutical composition of the present invention, wherein the pharmaceutical composition is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a binder, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or its solvate or crystal accounts for about 1% to 80% (weight / weight) of the total weight of the pharmaceutical composition, the disintegrant accounts for about 1% to 30% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 0% to 95% (weight / weight) of the total weight of the pharmaceutical composition. Further preferably, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 3% to 40% (weight / weight) of the total weight of the pharmaceutical composition, the disintegrant accounts for about 2% to 15% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0.5% to 5% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0.1% to 5% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 40% to 90% (weight / weight) of the total weight of the pharmaceutical composition. Further preferably, the pharmaceutical composition of the present invention is composed of a compound of formula (I) or a solvate or crystal thereof, a disintegrant, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) or a solvate or crystal thereof accounts for about 5% to 10% (weight / weight) of the total weight of the preparation, the disintegrant accounts for about 6% to 10% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0.5% to 1.5% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0.3% to 2% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 60% to 88% (weight / weight) of the total weight of the pharmaceutical composition. Another aspect of the present invention provides a method for preparing the composition of the present invention, comprising mixing the components in the pharmaceutical composition of the present invention.
[0036] In some embodiments, the present invention provides a method for preparing a pharmaceutical preparation of the present invention, the preparation comprising a compound of formula (I) or a solvate or crystal thereof and a disintegrant, the method comprising: mixing the compound of formula (I) or a solvate or crystal thereof and a disintegrant, and then granulating. In some specific embodiments, according to the method for preparing a pharmaceutical preparation of the present invention, the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose.
[0037] In some preferred embodiments, the present invention provides a method for preparing a pharmaceutical preparation of the present invention, the preparation comprising a compound of formula (I) or a solvate or crystal thereof, a filler and a disintegrant, the method comprising: mixing the compound of formula (I) or a solvate or crystal thereof with a filler and a disintegrant, and then granulating. In some specific embodiments, according to the method for preparing a pharmaceutical preparation of the present invention, the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol, starch, lactose, sugars, cellulose and inorganic salts; the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose.
[0038] In some preferred embodiments, the present invention provides a method for preparing a pharmaceutical preparation of the present invention, the preparation comprising a compound of formula (I) or a solvate or crystal thereof, a lubricant and a disintegrant, the method comprising: mixing the compound of formula (I) or a solvate or crystal thereof with a filler and a disintegrant, and then granulating. In some specific embodiments, according to the method for preparing a pharmaceutical preparation of the present invention, the lubricant is selected from one or more of magnesium stearate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol, talc, sodium stearyl fumarate, and glyceryl behenate; the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, or low-substituted hydroxypropyl cellulose.
[0039] In other preferred embodiments, the present invention provides a method for preparing a pharmaceutical preparation of the present invention, the preparation comprising a compound of formula (I) or a solvate or crystal thereof, a filler, a disintegrant and a lubricant, the method comprising: mixing the compound of formula (I) or a solvate or crystal thereof with a filler, a disintegrant and a lubricant, and granulating the step. In some specific embodiments, according to the method for preparing a pharmaceutical preparation of the present invention, the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol, starches, lactose, sugars, celluloses and inorganic salts; the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitate stearate, sodium lauryl sulfate and hydrogenated vegetable oil.
[0040] In other preferred embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, wherein the preparation comprises a compound of formula (I) or a solvate or crystal thereof, a filler, a disintegrant, a lubricant and a binder, and the method comprises: mixing the compound of formula (I) or a solvate or crystal thereof with the filler, disintegrant, lubricant and binder, and performing granulation. In some specific embodiments, according to the preparation method of the pharmaceutical preparation of the present invention, the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol, starches, lactose, sugars, celluloses and inorganic salts; the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate and hydrogenated vegetable oil; the binder is selected from one or more of povidone, hydroxypropyl methylcellulose and hydroxypropyl cellulose.
[0041] In other preferred embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, wherein the preparation comprises a compound of formula (I) or a solvate or crystal thereof, a filler, a disintegrant, a lubricant, a binder and a wetting agent, and the method comprises: mixing the compound of formula (I) or a solvate or crystal thereof with the filler, disintegrant, a lubricant, a binder and a wetting agent, and performing granulation. In some specific embodiments, according to the preparation method of the pharmaceutical preparation of the present invention, the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol, starches, lactose, sugars, celluloses and inorganic salts; the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate and hydrogenated vegetable oil; the binder is selected from one or more of polyvinylpyrrolidone, hydroxypropyl methylcellulose and hydroxypropyl cellulose; the wetting agent is water.
[0042] In other preferred embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, which comprises the steps of fully mixing the compound of formula (I) or its solvate or crystal and a filler, a disintegrant, a lubricant, a binder and a wetting agent, granulating, and capsule filling.
[0043] In other preferred embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, which comprises the steps of fully mixing the compound of formula (I) or its solvate or crystal and a filler, a disintegrant, a lubricant, a binder and a wetting agent, granulating, and pressing to form tablets.
[0044] In other preferred embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, the method comprising: adding fillers, disintegrants, lubricants, binders and wetting agents to the compound of formula (I) or its solvate or crystals as required to carry out stirring granulation, extrusion granulation, rotation granulation, spray one-step granulation, etc., or direct dry granulation. In addition, it can also be prepared by micro-pill drug application. In addition, it can also be granulated and crushed as required. Furthermore, it can be compressed into tablets or directly filled into capsules as required; it can also be further selectively added with disintegrants, fillers, lubricants, binders, antioxidants, colorants, etc. to the above-mentioned granules for compression into tablets or direct filling into capsules.
[0045] In some specific embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, the method comprising:
[0046] (1) uniformly mixing the compound of formula (I) or its solvate or crystal, a disintegrant and optional fillers, lubricants and binders;
[0047] (2) optionally adding an appropriate amount of a wetting agent to the mixed material of step (1) to perform wet granulation;
[0048] (3) drying and granulating the granules obtained in step (2);
[0049] (4) Optionally, uniformly mixing the granules of step (3) with a disintegrant and a lubricant;
[0050] (5) preparing a preparation from the mixture of step (4).
[0051] In some specific embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, the method comprising:
[0052] (1) sieving the compound of formula (I) or its solvate or crystal, disintegrant and optional filler, lubricant and binder, adding them into a wet granulator according to the prescribed amount and mixing them evenly;
[0053] (2) adding an appropriate amount of a wetting agent to the mixture of step (1) for wet granulation;
[0054] (3) drying the particles obtained in step (2) in a drying device;
[0055] (4) Optionally, the granules, disintegrant and lubricant of step (3) are added to a mixer with a replaceable barrel and mixed evenly;
[0056] (5) Pour the mixture from step (4) into a capsule filling machine to fill capsules.
[0057] In some specific embodiments, the present invention provides a method for preparing the pharmaceutical preparation of the present invention, the method comprising:
[0058] (1) sieving the compound of formula (I) or its solvate or crystal, disintegrant and optional filler, lubricant and binder, adding them into a wet granulator according to the prescribed amount and mixing them evenly;
[0059] (2) adding an appropriate amount of a wetting agent to the mixture of step (1) for wet granulation;
[0060] (3) drying the particles obtained in step (2) in a drying device;
[0061] (4) Optionally, the granules, disintegrant and lubricant of step (3) are added to a mixer with a replaceable barrel and mixed evenly;
[0062] (5) Pour the mixture from step (4) into a tablet press and compress it into tablets.
[0063] Another aspect of the present invention provides the use of the composition of the present invention in the preparation of a medicament for treating and / or preventing cancer, tissue proliferative diseases, fibrosis or inflammatory diseases, wherein the symptoms of the cancer, tissue proliferative diseases, fibrosis or inflammatory diseases include, but are not limited to: melanoma, papillary thyroid tumors, bile duct cancer, colon cancer, ovarian cancer, lung cancer, malignant lymphoma, cancer and sarcoma of the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumors or leukemia of the skin, colon, thyroid, lung and ovary, glioblastoma (glioma), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), sarcoma, non-small cell lung cancer, chondrosarcoma, bile duct cancer or angioimmunoblastic lymphoma, liver fibrosis and chronic kidney disease.
[0064] In the pharmaceutical composition of the present invention, any form or amorphous form of the compound of formula (I) can be used, and the obtained preparation has very good stability. In other embodiments, the crystalline form of the compound of formula (I) is used to prepare the pharmaceutical composition of the present invention.
[0065] The pharmaceutical composition provided by the present invention can be completely dissolved in vitro, has few impurities, good stability, and can simplify storage and transportation conditions.
[0066] Terminology
[0067] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0068] The term "solvate" refers to a form of the compound of the present invention that forms a solid or liquid complex by coordination with solvent molecules, and includes hydrates, ethanolates, acetonitrileates and the like.
[0069] The term "crystalline" refers to various solid forms of the compounds of the present invention, including crystalline and amorphous forms. "Hydrogen", "carbon" and "oxygen" in the compounds of the present invention include all isotopes thereof. Isotopes should be understood to include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include protium, tritium and deuterium, and isotopes of carbon include 13 C and 14 C, oxygen isotopes include 16 O and 18 O etc.
[0070] The term "API" refers to 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoline. DETAILED DESCRIPTION
[0071] The following representative examples are intended to better illustrate the present invention, but are not intended to limit the scope of protection of the present invention. Unless otherwise specified, the materials used in the following examples were commercially available.
[0072] Example 1 Preparation of 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)quinoline
[0073]
[0074] Step 1: Preparation of 2-bromo-1-(tetrahydro-2H-pyran-4-yl)ethan-1-one
[0075]
[0076] Under nitrogen protection, methanol (100 mL) and 1-(tetrahydro-2H-pyran-4-yl)ethanone (20.0 g, 156 mmol) were added to a 1000 mL three-necked flask in sequence, the temperature was lowered to below -15 °C, and liquid bromine was slowly added dropwise to maintain the temperature below -15 °C. After the addition, the temperature was raised to 0 °C, and the reaction was continued for 45 min, then raised to 10 °C, and the reaction was continued for 45 min. After the internal temperature was maintained below room temperature, 11 mol / L sulfuric acid (55 mL) was slowly added dropwise, and the reaction was continued overnight at room temperature. After monitoring the completion of the reaction, ethyl acetate and sodium chloride aqueous solution were added for extraction, and the organic layers were combined. The organic layers were adjusted to pH 7-8 with saturated sodium bicarbonate, and the organic layers were combined and concentrated under reduced pressure to obtain the title compound as a light yellow solid, a total of 28.5 g, yield: 87.5%; MS (ESI) m / z 207.0 [M+H] + .
[0077] Step 2: Preparation of 2-oxo-2-(tetrahydro-2H-pyran-4-yl)ethyl benzoate
[0078]
[0079] Dissolve benzoic acid (18.5 g, 151.4 mmol) in N,N-dimethylformamide (DMF, 495 mL), add potassium carbonate (38 g, 275.2 mmol), and then add 2-bromo-1-(tetrahydro-2H-pyran-4-yl)ethane-1-one (28.5 g, 137.6 mmol) to the system, and react at room temperature overnight. Add ethyl acetate to dilute, and wash with sodium chloride aqueous solution. Combine the organic phases. Concentrate under reduced pressure to obtain the title compound as a light yellow solid, a total of 30.0 g, yield: 88.2%; LC-MS m / z [M+H] + =249.
[0080] Step 3: Preparation of (Z)-1-(dimethylamino)-3-oxo-3-(tetrahydro-2H-pyran-4-yl)prop-1-en-2-yl benzoate
[0081]
[0082] Add 2-oxo-2-(tetrahydro-2H-pyran-4-yl)ethyl benzoate (95.0 g, 383 mmol) to 1,1-dimethoxy-N,N-dimethylmethylamine (795.15 mL, 5975.8 mmol), heat to 100 ° C, react for 2 h, then heat to 106 ° C, react for 2 h, monitor the reaction and return to room temperature after completion, concentrate to dryness under reduced pressure, add ethyl acetate to the system, wash with brine, and dry the organic phase with anhydrous sodium sulfate. Filter the organic phase, concentrate under reduced pressure to obtain the title compound as a red solid, a total of 107.9 g, yield: 93.1%, directly used in the next step. LC-MS m / z[M+H]+ =304.
[0083] Step 4: Preparation of 3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl benzoate
[0084]
[0085] To a 1000mL reaction bottle, acetic acid (376.1mL) and (Z)-1-(dimethylamino)-3-oxo-3-(tetrahydro-2H-pyran-4-yl)prop-1-en-2-ylbenzoate (32.56g, 107.46mmol) were added in sequence, and 80% hydrazine hydrate (37.6mL) was slowly added dropwise under an ice bath, and stirred overnight at room temperature after the addition. The reaction was monitored to the end point, ethyl acetate was added to the reaction solution, washed with water, the organic phases were combined, and washed with saturated sodium bicarbonate solution until the pH was 7-8, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a yellow oil, which was left at room temperature overnight to obtain a yellow solid title compound, a total of 28.0g, yield: 95.8%; LC-MSm / z[M+H] + =273.
[0086] Step 5: Preparation of 1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl benzoate
[0087]
[0088] To 1,2-dichloroethane (250 mL), 2,2'-bipyridine (17.7 g, 113.2 mmol) and copper acetate (20.6 g, 113.2 mmol) were added in sequence, and the mixture was reacted at 75 °C for 30 min. After cooling to room temperature, cyclopropylboric acid (17.5 g, 205.9 mmol), sodium carbonate (21.8 g, 205.9 mmol) and a solution of 3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-ylbenzoate (28.0 g, 102.9 mmol) in 1,2-dichloroethane (250 mL) were added in sequence, and the mixture was reacted at 75 °C for 4 h under an oxygen atmosphere. Monitor until the reaction end point, cool to room temperature, filter with diatomaceous earth, wash the filter cake with ethyl acetate, and concentrate the filtrate under reduced pressure to obtain the title compound as a reddish brown oil, 32.0 g in total, yield: 98.5%, which is directly used in the next step; LC-MS m / z [M+H] + =313.
[0089] Step 6: Preparation of 1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-ol
[0090]
[0091] Add 1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-ylbenzoate (32.0 g, 102.6 mmol) to methanol (308 mL) and react at room temperature for 2 h. Monitor the reaction until the end point, concentrate under reduced pressure to remove part of the methanol, adjust the pH to 6-7 with 1 mol / L dilute hydrochloric acid, extract with dichloromethane, and combine the organic layers. Concentrate under reduced pressure to dryness, and purify by column chromatography to obtain the title compound as a yellow solid, a total of 9.0 g, yield: 45%; LC-MS m / z [M+H] + =209.
[0092] Step 7: Preparation of 7-bromo-4-chloroquinoline
[0093]
[0094] Add 4.50 kg of acetonitrile to a 50L vertical jacketed reactor, start stirring, add 7-bromo-4-hydroxyquinoline (1.80 kg, 8.03 mol) and 4.00 kg of acetonitrile in sequence, and when the internal temperature drops below 10°C, add phosphorus oxychloride (1.85 kg, 12.05 mol) dropwise. After the addition is complete, heat and reflux with stirring for 1 to 3 hours, monitor to the reaction endpoint, cool the system to below 5°C, add 4 mol / L NaOH solution dropwise to adjust the pH to 7 to 8, add 42.00 kg of water, stir at room temperature for 1 to 2 hours, centrifuge the feed liquid, wash the filter cake with 5.00 kg of water, dry in vacuo, collect and weigh the solid to obtain a crude brown solid title compound, a total of 1.73 kg, yield: 88.8%.
[0095] To a 50L vertical jacketed reactor, 14.4kg of methyl tert-butyl ether and 1.73kg of crude 7-bromo-4-chloroquinoline were added in sequence, stirred at 50±5°C for 1 to 3 hours, filtered while hot, the filter cake was washed with methyl tert-butyl ether, the filtrate was concentrated to dryness under reduced pressure, and the obtained solid was vacuum dried. After drying, the solid was collected and weighed to obtain a refined product of the title compound as a yellow solid, totaling 1.54kg, with a yield of 89.0%.
[0096] Step 8: Preparation of 7-bromo-4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline
[0097]
[0098] Add 8.40 kg of acetonitrile to a 30 L glass reactor, start stirring, and add 7-bromo-4-chloroquinoline (1.26 kg, 5.18 mol), cesium carbonate (1.69 kg, 5.18 mol), 1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-ol (0.90 kg, 4.32 mol, 4.00 kg of acetonitrile for washing. Protect with nitrogen and heat to 70 ± 5 ℃ and stirred for 2 to 3 hours, then raised the temperature to reflux for 2 to 3 hours. When cooled to 70±5℃, filter while hot, wash the filter residue with dichloromethane, and concentrate the filtrate under reduced pressure until it becomes viscous. Add 14.00 kg of water, stir, centrifuge, wash the filter cake with 3.00 kg of water, and dry in vacuo at 50±5℃ for 10 to 20 hours. After drying, collect and weigh the solid to obtain a brown solid crude product 1 of the title compound, totaling 1.88 kg, with a crude product yield of 100.0%.
[0099] Add 6.40 kg of heptane and 1.88 kg of 7-bromo-4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline crude product 1 into a 10L four-necked flask, and stir at 25±5°C for 3 to 5 hours. Filter, wash the filter cake with 1.40 kg of heptane, and dry in vacuo at 50±5°C for 3 to 20 hours. After drying, collect and weigh the solid to obtain the title compound crude product 2 as a dark yellow solid, totaling 1.68 kg, with a yield of 89.4%.
[0100] Add 4.70 kg of anhydrous ethanol and 1.68 kg of 7-bromo-4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline crude product 2 to a 10L four-necked flask, heat to reflux, stir for 0.5 to 1 hour after dissolving, turn off the heating, cool naturally for crystallization, and when the internal temperature is lower than 30°C, open the external circulation and stir at -10 to -5°C for 1 to 3 hours. Centrifuge the feed liquid, wash the filter cake with 0.4 kg of cold ethanol (-10 to -5°C), and vacuum dry at 50±5°C for 10 to 20 hours. After drying, collect and weigh the solid to obtain a refined product of the title compound as a light yellow solid, totaling 1.35 kg, with a yield of 80.4%.
[0101] Step 9: Preparation of 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine
[0102]
[0103] Add 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride (1.20kg, 5.25mol) and 11.8kg acetonitrile to a 20L four-necked flask, start stirring, add sodium hydroxide (0.42kg, 10.50mol) and 36.00g water, stir vigorously at 25±5℃ for 3-15 hours; filter, wash with acetonitrile, concentrate the filtrate to dryness under reduced pressure, add 0.5g seed crystals, and dry under vacuum after solidification. After drying, collect and weigh the solid to obtain the title compound as a white solid, totaling 0.92kg, with a yield of 91.2%.
[0104] Step 10: Preparation of 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoline
[0105]
[0106] 7.10 kg of 1,4-dioxane was added to a 20 L four-necked flask, stirring was started, and 7-bromo-4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline (1.34 kg, 3.23 mol), 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (0.75 kg, 3.88 mol), potassium phosphate (K 3 PO 4 , 1.37 kg, 6.47 mol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (Xantphos, 37.40 g, 65.00 mmol), tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 , 29.6g, 32.00mmol). Protect with nitrogen and maintain nitrogen atmosphere. Heat to 95±5℃ and stir for 3-15 hours, turn off heating, filter while hot when the internal temperature drops to 70-80℃, wash with 1.6kg hot 1,4-dioxane (70-80℃), slowly pour the mother liquor into ice water, add N-acetyl-L-cysteine, stir for 1-1.5 hours, centrifuge, wash with 5.00kg water, and dry in vacuum. After drying, collect and weigh the solid to obtain the yellow solid crude product 1 of the title compound, totaling 1.41kg, with a yield of 83.1%.
[0107] Step 11: Purification of 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoline
[0108] 3.8 kg of ethyl acetate and 1.40 kg of crude 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)quinoline 1 were added to a 10L four-necked flask, and the mixture was heated to 55±5°C and stirred for 2 to 4 hours under nitrogen protection, and naturally cooled to an internal temperature below 30°C, and crystallized by stirring at -5 to -10°C for 1 to 3 hours, centrifuged, washed with 0.5 kg of cold ethyl acetate (-10 to -5°C), and vacuum dried to obtain a crude light yellow solid of the title compound 2. A total of 1.21 kg, with a yield of 85.8%.
[0109] 14.30 kg of anhydrous methanol and 1.20 kg of 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)quinoline crude product 2 were added to a 30 L glass reactor, and the temperature was raised to reflux under nitrogen protection to dissolve the clear solution. 0.12 kg of activated carbon and 0.12 kg of Thiol. Reflux for 1 to 1.5 hours, filter while hot, wash with hot methanol (50 to 60°C), concentrate the filtrate under reduced pressure, cool at -10 to -5°C for crystallization for 1 to 3 hours, centrifuge, wash with cold methanol (-10 to -5°C). Vacuum dry to obtain a total of 1.03 kg of the crude title compound 3 as an off-white solid. Yield 85.1%.
[0110] Add 9.50 kg of dichloromethane and 1.02 kg of crude 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)quinoline 3 to a 10L four-necked flask and start stirring. After the solution is clear, add 0.20 kg Thiol, stirred, filtered, washed with dichloromethane, slowly added 26.20 kg of heptane to the filtrate, stirred for 10 to 15 hours, filtered, washed the filter cake with 1.60 kg of heptane, and dried under vacuum to obtain a refined product of the title compound as a white solid, a total of 0.99 kg. Yield 97.1%. ESI-MS [M+H] + m / z:526.3, 1H NMR (400MHz, DMSO) δ8.59(d,J=5.2Hz,1H),8.17(d,J=11.2Hz,1H),7.94(s,1H),7.64( dd,J=11.2,2.4Hz,1H),7.45(d,J=2.4Hz,1H),6.56(d,J=5.2Hz,1H),4.91(s,2H),4.34 (t,J=5.1Hz,2H),4.02(t,J=5.2Hz,2H),3.88–3.71(m,2H),3.73–3.63(m,1H),3.30–3. 19(m,2H),2.82–2.65(m,1H),1.78–1.59(m,4H),1.12–1.01(m,2H),1.01–0.88(m,2H).
[0111] Example 2-19
[0112] Examples 2-19 shown in Tables 1 to 3 are preparations made using the compound of formula (I) (API for short) prepared in Example 1 of the present invention and different disintegrants, fillers, wetting agents, lubricants, etc.
[0113] Table 1
[0114]
[0115] Table 2
[0116]
[0117]
[0118] Table 3
[0119]
[0120] "\" indicates not added
[0121] The preparation method of Example 2-19 is as follows:
[0122] (1) Pretreatment of excipients and weighing of raw materials and excipients: API, lactose monohydrate, mannitol 160C, microcrystalline cellulose 101, hydroxypropyl cellulose-SSL, sodium starch glycolate, and low-substituted hydroxypropyl cellulose were weighed according to the prescription amounts of Examples 2-19 shown in Table 1-3, respectively, passed through a 60-mesh sieve, and shaken to mix for premixing;
[0123] (2) adding an appropriate amount of a wetting agent to the mixed material of step (1) to perform wet granulation;
[0124] (3) drying the granules obtained in step (2) in an oven at 60° C. and passing the dried granules through a sieve for size adjustment;
[0125] (4) adding the granules of step (3) and the prescription amounts of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, magnesium stearate, and sodium stearyl fumarate of Example 2-19 shown in Table 1-3 into a replaceable barrel mixer and mixing evenly;
[0126] (5) Pour the mixture from step (4) into a capsule filling machine to fill capsules.
[0127] Experimental Example 1: Evaluation of ALK5 kinase activity of compounds in vitro
[0128] 1. Experimental Materials
[0129] 1.1 Compounds
[0130] The compound of formula (I) of the present invention in Example 1 was prepared with DMSO to 10 mM and then diluted to 3.333 μM, 1.111 μM, 370 nM, 123 nM, 41 nM, 14 nM, 4.6 nM, 1.5 nM and 0.5 nM in sequence.
[0131] 1.2 Reagents and instruments
[0132] Reagents: ALK5, purchased from Carna, Cat. No. 09-141; p38α, purchased from Carna, Cat. No. 04-152; TGFβR1 peptide, purchased from SignalChem, Cat. No. T36-58; dimethyl sulfoxide (DMSO), purchased from Sigma, USA; EDTA, purchased from Sigma, USA; ADP-Glo Kinase Assay, purchased from Promega, Cat. No. v9102 / 3, 1× kinase buffer (40 mM Tris, pH 7.5, 0.10% BSA, 20 mM MgCl 2 , 1 mM DTT), prepared just before use.
[0133] Instrument: 2104 Multilabel Reader, purchased from Perkin Elmer, USA.
[0134] 2. Experimental Methods
[0135] 2.1 Preparation of 1x kinase buffer
[0136] 1x assay buffer
[0137] 40 mM Tris, pH 7.5
[0138] 20 mM MgCl 2
[0139] 0.10% BSA
[0140] 1mM DTT
[0141] 2.2 Compound preparation
[0142] 2.2.1 Compound dilution
[0143] 2.2.1.1 Prepare 50-fold compound: The final concentration of the compound is 10 μM, and it is prepared to 50 times the concentration, that is, 500 μM: Add 95 μl of 100% DMSO to the second well of the 96-well plate, and then add 5 μl of 10mM compound solution to prepare a 1000 μM compound solution. Add 60 μl of 100% DMSO to the other wells. Take 30 μl of the compound from the second well and add it to the third well, and make 3-fold dilutions in turn, for a total of 10 concentrations.
[0144] Dilution instrument: Automatic micropipette (Precision PRC384U).
[0145] 2.2.1.2 Use echo to transfer 100 nl of compound to the reaction plate.
[0146] 2.3 Kinase reaction
[0147] 2.3.1 Preparation of 2x kinase solution
[0148] Add kinase to 1x kinase buffer to form 2x enzyme solution. 100nl of 100% DMSO dissolved compound is already in the 384-well reaction plate. Add 2.5μl of 2x enzyme solution to the 384-well reaction plate. Incubate at room temperature for 10 minutes.
[0149] 2.3.2 Preparation of 2x substrate solution
[0150] Add FAM-labeled peptide and ATP to 1x kinase buffer to form 2x substrate solution. Add 2.5 μl of 2x substrate solution to the 384-well reaction plate.
[0151] 2.4 Kinase reaction
[0152] The 384-well plate was incubated at 28°C for 120 minutes.
[0153] 2.5 Detection of reaction results
[0154] 2.5.1 Equilibrate ADP-Glo reagent to room temperature.
[0155] 2.5.2 Transfer 5 μl of the reaction solution to a new reaction well of a 384-well plate.
[0156] 2.5.3 Transfer 5 μl ADP-Glo reagent to the reaction wells of the 384-well plate to terminate the reaction.
[0157] 2.5.4 Incubate at 28°C for 120 minutes.
[0158] 2.5.5 Transfer 10 μl of kinase assay reagent to each reaction well, shake for 1 minute, and let stand at room temperature for 30 minutes.
[0159] 2.6 Data Reading
[0160] The sample luminescence value was read on Envision.
[0161] 2.7 Curve Fitting
[0162] 2.7.1 Copying luminescence readings from Envision
[0163] 2.7.2 Convert the luminescence readings into inhibition percentage using the formula.
[0164] Percent inhibition = (max-sample RLU) / (max-min)*100. “min” is the fluorescence reading of the control sample without adding enzyme; “max” is the fluorescence reading of the sample with DMSO added as a control.
[0165] 2.7.3 Import the data into MS Excel and use XLFit excel add-in version 5.4.0.8 to perform curve fitting. The fitting formula is: Y = Bottom + (Top-Bottom) / (1 + (IC 50 / X)^HillSlope), the results are shown in Table 4.
[0166] Table 4
[0167]
[0168] From the above experimental results, it can be seen that the compounds of the present invention have good inhibitory activity on ALK5 kinase, and have low inhibitory effect on p38α, with high selectivity, indicating that the compounds of the present invention have lower side effects while producing higher therapeutic effects.
[0169] Experimental Example 2: Evaluation of Compounds by In Vitro Cell Luciferase Assay
[0170] 1. Experimental Materials
[0171] Test compound: the compound of formula (I) of the present invention in Example 1, prepared with DMSO to 4 mM, and then diluted 4-fold in sequence to 20000.00 nM, 5000.00 nM, 1250.00 nM, 312.5 nM, 78.125 nM, 19.53 nM, 4.88 nM, and 1.22 nM.
[0172] Luc-Smad2 / 3-NIH3T3 mouse fibroblasts (engineered to overexpress SMAD2,3-responsive promoter) were gifted by the laboratory of China Pharmaceutical University.
[0173] Reagents: DMEM, purchased from Invitrogen, USA; FBS, purchased from Invitrogen, USA; DMSO, purchased from Sigma, USA; Glo Lysis Buffer, purchased from Progema, USA; Bright-Glo Luciferase assay system, purchased from Promega, USA; TGFβ, purchased from PeproTech, USA.
[0174] Instrument: MD SpectraMax M3 multi-function microplate reader, purchased from Molecular Devices, USA.
[0175] 2. Experimental Methods
[0176] 2.1 Cell culture:
[0177] Cell recovery: Dissolve the cells in a 37°C water bath, then transfer to 15 mL of pre-warmed culture medium, centrifuge at 1000 rpm for 5 minutes, discard the culture medium, resuspend the cells in 15 mL of fresh culture medium, transfer to a 10 cm culture dish, and place at 37°C, 5% CO 2 After 24 hours, the cells were cultured in a fresh culture medium.
[0178] Cell passaging: Transfer the above revived cells to a 50 mL sterile centrifuge tube, centrifuge at 1000 rpm for 5 minutes, discard the culture medium, count the evenly dispersed cells, adjust the appropriate cell concentration to 15 mL of fresh culture medium, add it to a 10 cm culture dish, and place at 37 °C, 5% CO 2 cultured in an incubator.
[0179] 2.2 Experimental steps:
[0180] Day 1: Cell plating (transparent bottom 96-well plate)
[0181] Luc-Smad2 / 3-NIH3T3 cells were cultured normally in a 10 cm culture dish until the confluence reached 80%-90%. After digestion, the cells were collected in a 15 mL centrifuge tube and centrifuged at 1000 x g for 5 minutes. The supernatant was removed and the cells were resuspended in 1 mL of culture medium and diluted 10 times for counting. The cells were diluted according to the counting results and 4x10 3 / well cells into a 96-well plate (add 100 μl of resuspended cells to each well).
[0182] Day 2: Cell administration
[0183] Weigh 1-2 mg of the drug (weighed in advance) and prepare a 4 mM stock solution using DMSO. After 24 hours, remove the culture medium. Dilute the drug with 2% FBS culture medium and add 100 μl of 1x drug solution to make the final drug concentrations 20000.00 nM, 5000.00 nM, 1250.00 nM, 312.5 nM, 78.125 nM, 19.53 nM, 4.88 nM, and 1.22 nM, respectively. The final concentration of TGFβ1 in each well is 4 ng / mL, and it is diluted with 2% FBS culture medium together with the compound.
[0184] Day 3: Fluorescence detection experiment
[0185] Equilibrate Glo Lysis Buffer, Bright-glo luciferase assay system and cells to room temperature, remove cell supernatant, add 100μl glo Lysis Buffer to each well, shake slowly to dissolve cells evenly, and lyse at room temperature for 5mins. Then add 100μl Bright-glo luciferase assay system to each well, incubate at room temperature for 5 minutes, shake for 2 minutes, transfer 180μl supernatant to a 96-well plate with a white bottom, and detect chemiluminescent signals under the detection condition of 1s.
[0186] 2.3 Data processing: Graphpad Prism 5 software was used for nonlinear curve fitting and data analysis, and the IC 50 , the experimental results are shown in Table 5.
[0187] Table 5
[0188]
[0189] It can be seen from the above experiments that the compounds of the present invention exhibit good inhibitory activity on the TGFβ-ALK5-SMAD2 / 3 signaling pathway in NIH3T3 cells, and are very promising as therapeutic agents for various cancer-related diseases.
[0190] Experimental Example 3: Dissolution Test of Examples 2 to 19
[0191] Dissolution test method: Dissolution test method (Chinese Pharmacopoeia 2015 edition, Part IV, General Rules 0931, Method 2).
[0192] Specific operation: pH 4.5 sodium acetate / acetic acid buffer solution, pH 5.0 citric acid / sodium citrate buffer solution, pH 5.5 phosphate buffer solution, and pH 6.8 phosphate buffer solution were used as dissolution media; volume: 900 mL; dissolution conditions: temperature 37°C ± 0.5°C, paddle method, rotation speed 50 rpm; sampling time points: 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, end point (250 rpm / 30 min), determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the 2015 edition of the Chinese Pharmacopoeia), using an Agilent Eclipse Plus C18 column (4.6×100 mm, 3.5 μm) as the chromatographic column, 0.1% phosphoric acid aqueous solution-acetonitrile (35:65) as the mobile phase, the flow rate was 1 mL / min, the detection wavelength was 310 nm, and the column temperature was 30°C. Accurately measure 10 μL of the test solution and the reference solution, respectively, and inject them into the high performance liquid chromatograph. Record the chromatograms and calculate the dissolution amount of each particle by the peak area according to the external standard method. The solubility in pH 4.5 sodium acetate / acetic acid buffer solution is shown in Tables 6, 7, and 8.
[0193] Table 6
[0194]
[0195] Table 7
[0196]
[0197] Table 8
[0198]
[0199] The experimental results show that in the dissolution medium of pH 4.5 sodium acetate / acetic acid buffer solution, the preparations prepared in Examples 2 to 19 can be fully dissolved.
[0200] In addition, the inventors of the present invention found that the compound of formula (I) showed a high degree of pH dependence in pH 1.2, 3.0, 4.5, 5.0, and 6.8 media. In Examples 2-19, in pH 1.2 and 3.0 media, the solubility was more than 90% in 10 minutes, and the dissolution rate was too fast; in pH 4.5 and 5.0 media, the solubility showed a trend of slow increase, and with the extension of time, it was completely dissolved and reached a platform; in pH 4.5 medium, the dissolution amount could reach more than 85% in 30-45 minutes, but in pH 5.0 medium, the dissolution amount could reach more than 85% in 45-60 minutes; in pH 6.8 medium, the compound of formula (I) existed mainly in molecular form, with low solubility and incomplete dissolution.
[0201] Experimental Example 4: Stability
[0202] The preparations prepared in the above examples were placed under accelerated conditions (40°C ± 2°C, RH 75% ± 5%), high humidity conditions (25°C / 92.5% RH), and high temperature conditions (60°C) for 28 days and tested. The test results showed that the preparations of the present invention had stable properties, few impurities, and no significant changes were observed in various indicators.
[0203] From the above experimental results, it can be seen that the 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)-7-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)quinoline preparation containing a disintegrant of the present invention has complete dissolution and good stability, and meets the clinical medication needs; in addition, the prepared compound of formula (I) has good absorption properties and high relative bioavailability.
[0204] Although the present invention has been described in detail above, those skilled in the art will appreciate that various modifications and changes may be made to the present invention without departing from the spirit and scope of the present invention. The scope of the present invention is not limited to the detailed description above, but should be attributed to the claims.
Claims
1. A pharmaceutical composition comprising: (a) a compound of formula (I), and (b) a disintegrant.
2. The pharmaceutical composition according to claim 1, wherein the disintegrant is one or more of sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose and low-substituted hydroxypropyl cellulose.
3. The pharmaceutical composition according to claim 1 or 2, further comprising a binder.
4. The pharmaceutical composition according to claim 3, wherein the binder is selected from one or more of povidone, hypromellose and hydroxypropyl cellulose.
5. The pharmaceutical composition according to claim 1 or 2, further comprising a lubricant.
6. The pharmaceutical composition according to claim 3, further comprising a lubricant.
7. The pharmaceutical composition according to claim 4, further comprising a lubricant.
8. The pharmaceutical composition according to claim 7, wherein the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate and hydrogenated vegetable oil.
9. The pharmaceutical composition according to claim 1 or 2, further comprising a filler.
10. The pharmaceutical composition according to claim 3, further comprising a filler.
11. The pharmaceutical composition according to claim 4, further comprising a filler.
12. The pharmaceutical composition according to claim 6, further comprising a filler.
13. The pharmaceutical composition according to claim 8, further comprising a filler.
14. The pharmaceutical composition according to claim 13, wherein the filler is selected from one or more of magnesium carbonate, calcium sulfate dihydrate, mannitol, sugars and inorganic salts.
15. The pharmaceutical composition according to claim 13, wherein the filler is selected from one or more of microcrystalline cellulose and pregelatinized starch.
16. The pharmaceutical composition according to claim 13, wherein the filler is selected from one or more of starches, lactose and celluloses.
17. A pharmaceutical composition according to claim 1 or 2, which consists of a compound of formula (I), a disintegrant, a binder, a lubricant and a filler, wherein based on the amount of the compound of formula (I), the compound of formula (I) accounts for about 1% to 80% (weight / weight) of the total weight of the pharmaceutical composition, the disintegrant accounts for about 1% to 30% (weight / weight) of the total weight of the pharmaceutical composition, the binder accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, the lubricant accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, and the filler accounts for about 0% to 95% (weight / weight) of the total weight of the pharmaceutical composition.
18. The pharmaceutical composition according to claim 17, wherein the disintegrant is selected from one or more of sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose; wherein the binder is selected from one or more of polyvinylpyrrolidone, hydroxypropyl methylcellulose and hydroxypropyl cellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate and hydrogenated vegetable oil; the filler is selected from one or more of magnesium carbonate, calcium sulfate dihydrate, mannitol, sugars and inorganic salts.
19. The pharmaceutical composition according to claim 17, wherein the disintegrant is selected from one or more of sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose; wherein the binder is selected from one or more of polyvinylpyrrolidone, hydroxypropyl methylcellulose and hydroxypropyl cellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate and hydrogenated vegetable oil; the filler is selected from one or more of microcrystalline cellulose and pregelatinized starch.
20. The pharmaceutical composition according to claim 17, wherein the disintegrant is selected from one or more of sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropylcellulose; wherein the binder is selected from one or more of polyvinylpyrrolidone, hydroxypropylmethylcellulose and hydroxypropylcellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate and hydrogenated vegetable oil; the filler is selected from one or more of starch, lactose and cellulose.
21. A pharmaceutical preparation comprising the pharmaceutical composition according to any one of claims 1 to 20.
22. The pharmaceutical preparation according to claim 21, wherein the pharmaceutical preparation is a tablet, granule, powder, sustained release formulation, pill, capsule, lozenge or cachet.
23. A method for preparing the pharmaceutical preparation according to claim 21, comprising: (1) mixing the compound of formula (I), disintegrant, filler, lubricant and binder uniformly; (2) optionally adding an appropriate amount of a wetting agent to the mixed material of step (1) to perform wet granulation; (3) drying the particles obtained in step (2); (4) Optionally, uniformly mixing the particles of step (3) with a filler and a lubricant; (5) preparing a preparation from the mixture of step (4);
Citation Information
Patent Citations
Composition containing substituted pyrimidine type PI3K inhibitor and use of composition
CN109512823A
Pharmaceutical composition containing quinoline derivative
CN110769825A
